ID: ALA283051

Max Phase: Preclinical

Molecular Formula: C30H20ClN3O

Molecular Weight: 473.96

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cn1cncc1C(O)(C#Cc1ccc(Cl)cc1)c1ccc(C#N)c(-c2cccc3ccccc23)c1

Standard InChI:  InChI=1S/C30H20ClN3O/c1-34-20-33-19-29(34)30(35,16-15-21-9-13-25(31)14-10-21)24-12-11-23(18-32)28(17-24)27-8-4-6-22-5-2-3-7-26(22)27/h2-14,17,19-20,35H,1H3

Standard InChI Key:  RHTSWGZKPCQUKZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 473.96

Molecular Weight (Monoisotopic): 473.1295

AlogP: 6.05

#Rotatable Bonds: 3

Polar Surface Area: 61.84

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.18

CX Basic pKa: 5.87

CX LogP: 6.10

CX LogD: 6.09

Aromatic Rings: 5

Heavy Atoms: 35

QED Weighted: 0.32

Np Likeness Score: -0.93

References

1. Lin NH, Wang L, Cohen J, Gu WZ, Frost D, Zhang H, Rosenberg S, Sham H..  (2003)  Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.,  13  (7): [PMID:12657267] [10.1016/s0960-894x(03)00122-7]

Source

Source(1):

• Scientific Literature